KRRONasdaqPharmaceutical PreparationsFiscal year ends December 31

Korro Bio, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$8.91+0.42 (+4.95%)

Close on Oct 19, 2026

Market cap: $156.98M
P/E (TTM): –
Dividend yield: –

Dividends

Korro Bio has not reported a dividend

No dividend per share appears in Korro Bio's annual filings since fiscal 2017.

Where these numbers come from

Parsed from the XBRL in Korro Bio's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-130 reverse split on Mar 26, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is KRRO.

Revenue growth-62.1% · median -55.0%

Operating margin-4625.5% · median -2510.6%

Net margin-4477.1% · median -3040.7%

Company	Revenue	Growth
PRQR	€15.91M	-15.9%
TRDA	$4.69M	-94.1%
CAMP	$4.22M	+40.2%
KRRO	$2.38M	-62.1%
SLN	$615.00K	-97.7%
NGNE	–	–

Company

Next earnings (est.): Nov 11, 2026, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 58
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 1703647

Advertisement
300 × 250